Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Core Insights - Viking Therapeutics, Inc. has appointed Neil Aubuchon as chief commercial officer, bringing over two decades of experience in the biopharmaceutical industry, particularly in global commercialization and marketing within the cardiometabolic space [1][3] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, leveraging expertise in metabolism to improve patients' lives [4] - The company's clinical programs include VK2735, a dual agonist for GLP-1 and GIP receptors, currently in Phase 3 trials for obesity, and VK2809, a selective thyroid hormone receptor beta agonist for lipid and metabolic disorders [4] Product Development - VK2735 is being evaluated in two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2) for obesity, with previous trials showing a favorable safety and tolerability profile [4] - VK2809 has successfully met primary and secondary endpoints in a Phase 2b study for non-alcoholic steatohepatitis (NASH) and fibrosis, demonstrating significant reductions in LDL-C and liver fat content in a Phase 2a trial for non-alcoholic fatty liver disease (NAFLD) [4] Strategic Direction - The appointment of Neil Aubuchon is seen as a strategic move to enhance Viking's commercialization capabilities for VK2735 and to engage with potential strategic partners, positioning the company for future commercial success [2][4]